A Clinical Trial Evaluating JYP0035 Capsule Monotherapy in Patients With Advanced Solid Tumors
Status:
Not yet recruiting
Trial end date:
2025-12-15
Target enrollment:
Participant gender:
Summary
The goal of this Phase I clinical trial is to evaluate the safety, tolerability, and
pharmacokinetic characteristics of the JYP0035 capsule in patients with advanced solid
tumors. The main questions it aims to answer are:
- What is the safety profile of JYP0035 when administered to these patients?
- How does JYP0035 capsule behave in the body pharmacokinetically?
Participants will:
- Receive escalating doses of JYP0035 capsule during the dose-escalation phase (PART-1).
- Continue with the identified dose in the dose-expansion phase (PART-2).
As this is a single-arm study, there is no comparison group.